Ken Griffin Onconova Therapeutics, Inc. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.57 - $1.0 $47,989 - $84,192	84,192 Added 228.66%	121,011 $71,000
Q1 2024 May 15, 2024	BUY	$0.67 - $1.01 $24,668 - $37,187	36,819 New	36,819 $37,000
Q4 2022 Feb 14, 2023	SELL	$0.63 - $0.97 $15,163 - $23,346	-24,069 Reduced 56.29%	18,689 $12,000
Q3 2022 Nov 14, 2022	SELL	$0.95 - $1.45 $15,916 - $24,293	-16,754 Reduced 28.15%	42,758 $38,000

249K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.